Alnylam Pharma (ALNY) Tops Q2 EPS by 16c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. EXPE
3. FIS
4. ARM
5. BROS
6. QCOM
7. ZG
8. DDOG
9. EW
10. CPAY

Go back to Alnylam Pharma (ALNY) Tops Q2 EPS by 16c

Alnylam Pharmaceuticals Reports Second Quarter 2018 Financial Results and Highlights Recent Period Activity

August 2, 2018 8:00 AM EDT

Received Positive CHMP Opinion for ONPATTRO in Europe for the Treatment of hATTR Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy and On Track for August 11 PDUFA Date in U.S.

Achieved Robust Enrollment in ENVISION Phase 3 Study of Givosiran and On Track to Report Topline Results from Interim Analysis for Potential Accelerated Approval

Achieved Regulatory Alignment for Phase 3 Studies of Lumasiran and ALN-TTRsc02

Maintained Strong Balance Sheet with $1.48 Billion in Cash and Expects to End 2018 with Approximately $1.0 Billion in Cash

CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More